Docetaxel (Taxotere)

DRUG4 trials

Sponsors

University of Michigan Rogel Cancer Center, M.D. Anderson Cancer Center, National Cancer Center, Korea, Marengo Therapeutics, Inc.

Conditions

Abdominal NeoplasmAdvanced CancerAdvanced Solid TumorsCarcinomaColorectal CancerEpstein-Barr Virus InfectionsGenital Neoplasm, FemaleLung Neoplasm

Phase 1

Docetaxel and Sirolimus in Patients With Advanced Malignancies

CompletedNCT01054313

M.D. Anderson Cancer CenterAdvanced Cancer

Start: 2010-01-31End: 2014-10-31Updated: 2015-10-07

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

RecruitingNCT05592626

Marengo Therapeutics, Inc.Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms +11

Start: 2023-01-04End: 2027-09-01Target: 366Updated: 2026-08-11

Phase 2

Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy

TerminatedNCT00480857

University of Michigan Rogel Cancer CenterProstate Cancer

Start: 2007-03-31End: 2014-07-31Updated: 2017-10-06

Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.

National Cancer Center, KoreaSarcoma

Start: 2008-04-30End: 2014-12-31Target: 35Updated: 2014-09-25

Related Papers

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression

Journal for ImmunoTherapy of Cancer2026-07-01

Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors resistant to anti-PD(L)-1.

Journal of Clinical Oncology2025-05-28

Trial START-001: A phase 1/2 study of STAR0602, a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors post checkpoint inhibitor (CPI) treatment.

Journal of Clinical Oncology2023-06-011 citations

A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.

2014-08-2814 citations